Nuwellis, Inc. NUWE
Biotechnology: Electromedical & Electrotherapeutic Apparatus · data as of November 13, 2026
Nuwellis, Inc. (NUWE) is a healthcare company listed in the US with a market value of about $3M. In the twelve months to September 30, 2026 it had revenue of $9M and net income of -$14M, a net margin of -152.8%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 2% a year, a 5-year average ROIC of -190%.
About Nuwellis
Nuwellis is listed in the US and classified in biotechnology: electromedical & electrotherapeutic apparatus. Revenue went from $295000 in 2014 to $8M in 2025, growth of about 35.4% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 583473% over three years (dilution for shareholders). It spends 33% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9M | $8M | $9M | $9M | $9M | $8M | $7M | $6M | $5M | $4M | $1M |
| Net income | -$14M | -$18M | -$11M | -$20M | -$15M | -$20M | -$16M | -$18M | -$17M | -$13M | -$16M |
| Free cash flow | -$12M | -$11M | -$10M | -$18M | -$15M | -$18M | -$17M | -$17M | -$15M | -$12M | -$16M |
| EPS (diluted) | $-19.94 | $-25.39 | $-353.30 | $-15122.63 | $-122819.18 | $-419481.51 | $-1557587.33 | $-40713318.28 | $-184773466.86 | $-2302038866.54 | $-32567730308.69 |
| Net margin | -152.8% | -211.9% | -127.8% | -228.0% | -170.0% | -246.9% | -212.8% | -328.7% | -340.8% | -376.6% | -1225.1% |
| ROIC | — | -299.3% | -122.7% | -371.4% | -101.9% | -57.0% | -81.1% | -586.9% | -226.7% | -72.1% | -888.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Nuwellis pay a dividend?
Not currently.
Is Nuwellis a good stock to buy?
We do not give buy or sell advice. Nuwellis scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.